We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Panbela Therapeutics Inc | NASDAQ:PBLA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.11 | 1.12 | 1.13 | 0 | 01:00:00 |
June 15, 2022
|
Date of Report (Date of Earliest Event Reported)
|
Panbela Therapeutics, Inc
|
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
001-39468
|
88-2805017
|
||
(State of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
712 Vista Blvd #305
Waconia, Minnesota
|
55387
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(952) 479-1196
|
(Registrant’s Telephone Number, Including Area Code)
|
Canary Merger Holdings, Inc.
|
(Former Name or Former Address, if Changed Since Last Report.)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
||
Common Stock, $0.001 par value
|
PBLA
|
The Nasdaq Stock Market LLC
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
Item 2.01
|
Completion of Acquisition or Disposition of Assets.
|
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
|
Item 3.01.
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
Item 3.02
|
Unregistered Sales of Equity Securities.
|
Item 3.03
|
Material Modification to Rights of Security Holders.
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
Item 7.01
|
Regulation FD Disclosure.
|
Item 8.01
|
Other Items.
|
Item 9.01
|
Financial Exhibits.
|
Exhibit No.
|
Description
|
Method of Filing
|
||
2.1*
|
Incorporated by reference
|
|||
3.1
|
Filed electronically
|
|||
3.2
|
Filed electronically
|
|||
4.1
|
Incorporated by reference
|
|||
10.1
|
Filed electronically
|
|||
10.2
|
Filed electronically
|
|||
10.3
|
Filed electronically
|
|||
10.4
|
Filed electronically
|
|||
10.5
|
Filed electronically
|
|||
10.6
|
Filed electronically
|
|||
23.1
|
Filed electronically
|
|||
99.1
|
Furnished electronically
|
|||
99.2
|
Incorporated by reference
|
|||
99.3
|
Filed electronically
|
|||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
*
|
Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished to the SEC upon request; provided, however, that the parties may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any document so furnished.
|
PANBELA THERAPEUTICS, INC.
|
|||
Date: June 16, 2022
|
By:
|
/s/ Susan Horvath
|
|
Susan Horvath
|
|||
Chief Financial Officer
|
1 Year Panbela Therapeutics Chart |
1 Month Panbela Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions